Importantly, compared to non-malignant cells, primary malignant cells are more sensitive to the inhibition of FASN and SREBP, making the combination of FASN and SREBP inhibitors a promising novel therapeutic strategy in CTCL. This evidence concerns the gene FASN and primary cutaneous T-cell non-Hodgkin lymphoma.